Inoviq Ltd · ASX:IIQ
Inoviq — Shareholder Meeting (November 2020)
38 slides from Inoviq's shareholder meeting presentation, Nov 26, 2020
Slide 1: Annual General Meeting
BARD1 Annual General Meeting November 2020 Building a leading diagnostics company
Slide 2: Agenda
Annual General Meeting Agenda •Business of Meeting: •Chairman’s Opening • Introductions • Resolutions • Questions •Close • CEO Presentation • Questions Annual General Meeting November 2020 Page 2
Slide 3: Item of Business
Annual General Meeting Item of Business Item 1 ‐ To table and consider the Annual Report of the Company for the financial year ended 30 June 2020, including the financial report, the declaration of the directors, the Directors’ Report, the Remuneration Report, and the Auditor’s Report. Annual Genera
Slide 4: Items of Business - Resolutions
Annual General Meeting Items of Business - Resolutions Item 2, resolution 1, is the Adoption of the Remuneration Report: That for the purpose of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report for the Company and its controlled entities for the year ended
Slide 5: Items of Business - Resolutions
Annual General Meeting Items of Business - Resolutions Item 3, resolution 2, Election of Professor Allan Cripps as Director: That, pursuant to and in accordance with Listing Rule 14.4 and articles 6.2(b) and 6.3(j) of the Constitution and for all other purposes, Professor Allan Cripps, Director, who
Slide 6: Items of Business - Resolutions
Annual General Meeting Items of Business - Resolutions Item 4, resolution 3, Election of Dr Geoffrey Cumming as Director: That, pursuant to and in accordance with Listing Rule 14.4 and articles 6.2(b) and 6.3(j) of the Constitution and for all other purposes, Dr Geoffrey Cumming, Director, who was a
Slide 7: Items of Business - Resolutions
Annual General Meeting Items of Business - Resolutions Item 6, resolution 5, Is the approval of increased placement capacity: That pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the issue of Equity Securities up to 10% of the issued capital of t
Slide 8: Items of Business - Resolutions
Annual General Meeting Items of Business - Resolutions Item 7, resolution 6, is the approval of a Share Consolidation: That, in accordance with section 254H of the Corporations Act 2001 (Cth) (Act) and clause 2.4 of the Company's constitution, with immediate effect on Friday, 27 November 2020, all o
Slide 9: Contacts
Contacts BARD1 Life Sciences Ltd 23 Normanby Road Notting Hill VIC 3168 Australia P +61 3 9548 7586 E info@bard1.com W www.bard1.com Dr Geoff Cumming | Chairman E geoff.cumming@bard1.com M 0417 203 021 Tony Di Pietro | CFO & Company Secretary E tdipietro@bard1.com M 0410 765 631 Annual General Meeti
Slide 10: CEO Presentation
BARD1 CEO Presentation November 2020 Building a leading diagnostics company
Slide 11: 2020 highlights
2020 highlights Corporate Commercial Research & Financial Development • Completed Sienna acquisition • Strategic business review • Completed RUO BARD1 Kit • Cash balance of $8.9m at 30 delivering multiple technology completed focusing on realising optimisation in ovarian cancer September 2020 platfo
Slide 12: BARD1's pillars for commercial success
BARD1’s pillars for commercial success 01 02 03 04 05 06 Large market Game- Robust Advancing Growth Experienced opportunities changing pipeline commerciali focused leadership technologies sation Focused Leveraging Multiple Commercialising Growth Leadership team on cancer unique marketed and products
Slide 13: Large global cancer diagnostics market
Cancer diagnostics market by cancer type2,3,4 01 Large global cancer diagnostics market Lung Cancer Bladder Cancer US$3.6b US$320m • Global cancer burden of 43.8m people living with cancer, 18.1m new cases and 16.4m deaths in 20181 • Global cancer diagnostics market Pancreatic Breast Cancer expected
Slide 14: Early cancer diagnosis: an unmet need
Early cancer diagnosis 5-year survival Average Early Late An unmet need Bladder 77% 96% 5.5% Breast 90% 99% 28% Lung 20% 59% 6% • Most current tests fail to accurately and reliably Ovarian 49% 93% 30% detect early-stage cancer, resulting in missed diagnosis, over-diagnosis and over-treatment Pancrea
Slide 15: Game-changing technology platforms
02 Game-changing technology platforms h N hTERT BARD1 SubB2M NET Antibody-based assay to Biomarker technology Unique pan-cancer probe Proprietary molecular detect hTERT, a component covering various BARD1 specific for a sugar found matrix that can be custom- of telomerase, in cells. tumour-associate
Slide 16: Best-in-class products and pipeline
03 Strong pipeline across the cancer diagnostics continuum Best-in-class products and pipeline Prediction Screening Diagnosis Theranosis Monitoring In-market and development-stage products Before diagnosis After diagnosis for multiple cancer indications *RUO = Research Use Only; ELLBA = Enzyme Linke
Slide 17: hTERT Test
h hTERT Test Revenue generating product hTERT test Current status • Immunocytochemistry (ICC) assay that detects • Distributors appointed in USA, Europe & Asia hTERT • Generating revenue & reimbursable in USA • Adjunct to urine cytology, assisting in the diagnosis of bladder cancer Market growth str
Slide 18: BARD1 biomarker platform
BARD1 biomarker platform In the normal cell, BARD1 binds to BRCA1 to control cell growth Early cancer detection Cancer cells express variant BARD1 proteins that drive tumour formation and are correlated with cancer progression and poor prognosis Cancer patient’s immune system produces autoantibodies
Slide 19: BARD1 autoantibody tests
BARD1 autoantibody tests Early cancer detection Potential to detect cancer early, save Product Study n AUC Sensitivity Specificity lives and reduce healthcare costs (cancer:normal) BARD1 OC-CA125 400 0.95 88% 93% Ovarian (ave-risk) (200:200) • BARD1 AAb tests in development with preclinical OC-R001
Slide 20: SubB2M pan-cancer probe
SubB2M pan-cancer probe Potential game-changer Many human cancers express glycans terminating in Neu5Gc and secrete them into the circulation. Neu5Gc is not present in cancer-free humans. • Exclusive worldwide license to SubB2M from University of Adelaide • SubB2M binds to highly specific cancer bio
Slide 21: SubB2M-based liquid biopsy pipeline
SubB2M-based liquid biopsy pipeline • Developing first-in-class new SubB2M test (ELLBA) A B for monitoring treatment response in various cancers • Developing SubB2M + cancer-specific biomarker tests (ELISA) for diagnosis and monitoring recurrence • Potential to improve specificity of existing commer
Slide 22: Molecular NET
N Molecular NET Biomarker capture platform Potential to revolutionise liquid biopsy sample preparation • Proprietary Molecular NETs - matrices composed of specific ligands, linkers and spacers to capture target biomarkers Magnetic Bead • Advanced capture technology based on affinity capture and size
Slide 23: Molecular NET NETs pipeline
N Molecular NET NETs pipeline PARTNERED CUSTOMISED NETs RUO EXO-NET EXO-NET • Designed to capture and purify • EXO-NET combined with proprietary • Develop and manufacture customised NETs exosomes for research purposes exosome biomarkers from partners for exosome diagnostics & therapeutics, or • Targ
Slide 24: Commercialisation strategy
04 Commercialisation strategy LDT IVD Pathway Launch pipeline products as LDTs through a CLIA certified Pathway Initiate Pre-Submission meeting with FDA to determine IVDclinical “High Complexity” Laboratory trial requirements for FDA clearance or approval • Fast-to-market pathway • Deeper market acc
Slide 25: Growth focused
05 Growth focused h • Building a leading diagnostics company hTERT BARD1 • 4 unique technology platforms with out-licensing opportunities • In-market revenue generating product • Deep diagnostic pipeline for breast, ovarian, N prostate, lung & pancreatic cancers being advanced towards commercialisat
Slide 26: Biotechnology experienced management
06 Biotechnology experienced management DR LEEARNE HINCH DR PETER FRENCH PhD CARL STUBBINGS TONY DI PIETRO Chief Executive Officer Chief Scientific Officer Chief Operations Officer Chief Financial Officer & Company Secretary Dr Leearne Hinch BSc BVMS MBA is Dr Peter French BSc MSc PhD Carl Stubbings
Slide 27: Snapshot
Snapshot Financial Information (24/11/20) Substantial Holders (24/11/20) # Shares % Holding Merchant Funds Management Pty Ltd 318,137,725 13.29% Mr Jeffrey Gerard Emmanuel 196,820,347 8.22% Ticker Ordinary Market David Williams 134,170,000 5.60% Shares Capitalisation Dr Irmgard Irminger-Finger 123,6
Slide 28: Value inflection points
Value inflection points Gained new Secure hTERT Launch hTERT Secure BARD1- BARD1-Ovarian high-volume registration and RUO internal hTERT Breast clinical results laboratory first order in South EXO-NET study registration preclinical Korea product results and first results order in China 4Q CY2020 1Q
Slide 29: Disclaimer
Disclaimer This presentation has been prepared by BARD1 Life appropriateness of the information having regard to their “believes”, or variations (including negative variations) of Sciences Limited (“BARD1” or the “Company”) based own objectives, financial situation and needs, and seek such words and
Slide 30: Contacts
Contacts BARD1 Life Sciences Ltd 23 Normanby Road Notting Hill VIC 3168 Australia P +61 3 9548 7586 E info@bard1.com W www.bard1.com Dr Leearne Hinch | CEO E leearne@bard1.com M 0400414416 Carl Stubbings | COO E cstubbings@bard1.com M 0423666374 BARD1 CEO Presentation November 2020 Page 30
Slide 31: Healthcare experienced board
Healthcare experienced board DR GEOFF CUMMING PhD Non-Executive Chairman MAX JOHNSTON Non-Executive Director PHILIP POWELL Non-Executive Director Healthcare and biotechnology director with Healthcare industry director and international business Healthcare industry director and chartered accountant e
Slide 32: Patent portfolio
Patent portfolio Patent Family BARD1 Title Granted Pending Expiry PCT/FR01/02731 Truncated BARD1 protein, and its diagnostic JP, US JP 2021 (WO/2002/018536 and therapeutic uses US 2024 ) PCT/IB2011/053635 BARD1 isoforms in lung and colorectal AU, CA, CN, EP, BR, SG, US 2031 Strong patent portfolio (
Slide 33: Chairman's Running Sheet/Transcript
Chairman’s Running Sheet/Transcript Annual General Meeting of BARD1 Life Sciences Limited 4.00pm, Thursday 26 November 2020 NOTE: BEFORE DECLARING THE MEETING OPEN – CHAIR TO CONFIRM WITH COMPANY SECRETARY THAT: 1. A QUORUM IS PRESENT, AND 2. THE AUDITOR IS ON THE LINE. (First slide of the presentat
Slide 34: Chairman's transcript: voting and introductions
meeting, a new polling icon will appear. Selecting this icon will bring up a list of resolutions and present you with voting options. To cast your vote simply select one of the options. There is no need to hit a Submit or Enter button as the vote is automatically recorded. You do however have the ab
Slide 35: Chairman's transcript: proxy votes and business of the meeting
votes received to determine the outcome of the resolutions. The results of the resolutions will be notified via the ASX platform. Proxy Votes Shareholders should be aware that the Company has received proxies, representing approximately 925 million shares, for the resolutions. Undirected proxies app
Slide 36: Chairman's transcript: remuneration report resolution
for the year ended 30 June 2020 is approved and adopted on the terms and conditions set out in the Explanatory Statement. The Remuneration Report sets out BARD1’s remuneration policy and provides details of the remuneration arrangements in place for Directors and Key Management Personnel. The vote o
Slide 37: Chairman's transcript: director elections and resolutions
who was appointed on 28 July 2020, retires and being eligible, is elected as a Director on the terms and conditions in the Explanatory Statement. Thank you, I will now hand back the reigns to Geoff. (Next slide - Seventh slide of AGM presentation to be shown) Item 6, resolution 5, requiring a vote o
Slide 38: Chairman's transcript: voting closed
(wait approximately 90 seconds) Voting is now closed. The results of these votes will be released to the stock exchange before the market opens in the morning. I will now hand over to CEO, Dr Leearne Hinch who will provide an update on the company’s progress and future plans. (Lead on to the CEO pre